DR. MONICA FEDEROFF (Orcid ID : 0000-0002-7920-2136)
DR. AMIT ANAND (Orcid ID : 0000-0003-1016-6904)
DR. CYNTHIA CALKIN (Orcid ID : 0000-0003-4673-3990)
DR. WILLIAM CORYELL (Orcid ID : 0000-0003-3989-7276)
DR. KEMING GAO (Orcid ID : 0000-0003-1130-2461)
DR. PETTER JAKOBSEN (Orcid ID : 0000-0002-7671-2456)
DR. JOHN NURNBERGER (Orcid ID : 0000-0002-7674-1767)
DR. MARTIN ALDA (Orcid ID : 0000-0001-9544-3944)
DR. PETER P ZANDI (Orcid ID : 0000-0001-8423-2623)

Article type : Original Article

Correction of depression-associated circadian rhythm abnormalities is associated with lithium-response in bipolar disorder

Monica Federoff[1]*, Michael J. McCarthy[1,2]*, Amit Anand[3], Wade H. Berrettini[4], Holli Bertram[5], Abesh Bhattacharjee[1,2], Cynthia V. Calkin[6], Carla Conroy[3], William H. Coryell[7], Nicole D'Arcangelo[3], Anna DeModena[2], Carrie Fisher[8], Scott Feeder[9], Nicole Frazier[5], Mark Frye[9], Keming Gao[3], Julie Garnham[6], Elliot Gershon[10], Ney Alliey-Rodriguez[10], Kara Glazer[11], Fernando Goes[11],Toyomi Karberg[3], Gloria Harrington[5], Petter Jakobsen[12,13], Masoud Kamali[5], Marisa Kelly[5], Susan G. Leckband[2], Falk Lohoff[4], Adam Maihofer[1], Melvin G. McInnis[5], Francis Mondimore[11], Gunnar Morken[14], John I. Nurnberger[8], Ketil J. Oedegaard[12,13], Megan Ritchey[11], Kelly Ryan[5], Martha Schinagle[3], Helle Schoeyen[13,15], Candice Schwebel[4], Martha Shaw[10], Paul D. Shilling[1], Claire Slaney[6], Andrea Stautland[13], Bruce Tarwater[7], Joseph R.

Calabrese[3], Martin Alda[6], Caroline M. Nievergelt[1], Peter P. Zandi[11], John R. Kelsoe, MD[1]
*authors contributed equally

Affiliations:

1 Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
2 Department of Psychiatry, VA San Diego Healthcare System, La Jolla, CA, USA
3 Department of Psychiatry, Case Western Reserve University, Cleveland, OH
4 University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
5 University of Michigan, Ann Arbor, MI
6 Dalhousie University, Halifax, Canada
7 University of Iowa, Iowa City, IA
8. Departments of Psychiatry and Medical and Molecular Genetics, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN
9 Mayo Clinic, Rochester, MN
10 University of Chicago, Chicago, IL
11 Department of Psychiatry and Behavioral Sciences, The Johns Hopkins School of Medicine, Baltimore, MD
12 NORMENT, Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
13 Department of Clinical Medicine, University of Bergen, Norway
14 Division of Psychiatry, St. Olav University Hospital of Trondheim and Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
15 Clinic of Adult Psychiatry, Stavanger University Hospital, Stavanger, Norway

Corresponding Author:
Michael J. McCarthy
VA San Diego Healthcare System
3350 La Jolla Village Dr MC116A
San Diego, CA 92161
(858)-642-1520
mmccarthy@health.ucsd.edu

Key words: Bipolar disorder, lithium, circadian rhythm, chronotype, sleep
Running Title: Circadian Symptoms and Lithium Response

Abstract

Background: Bipolar disorder (BD) is characterized by episodes of depression and mania and disrupted circadian rhythms. Lithium is an effective therapy for BD, but only 30-40% of patients are fully responsive. Preclinical models show that lithium alters circadian rhythms. However, it is unknown if the circadian rhythm effects of lithium are essential to its therapeutic properties.
Methods: In secondary analyses of a multi-center, prospective, trial of lithium for BD, we examined the relationship between circadian rhythms and therapeutic response to lithium. Using standardized instruments, we measured morningness, diurnal changes in mood, sleep and energy (circadian rhythm disturbances) in a cross-sectional study of 386 BD subjects with varying lithium exposure histories. Next, we tracked symptoms of depression and mania prospectively over 12 weeks in subset of 88 BD patients initiating treatment with lithium. Total, circadian, and affective mood symptoms were scored separately and analyzed.
Results: Subjects with no prior lithium exposure had the most circadian disruption, while patients stable on lithium monotherapy had the least. Patients who were stable on lithium with another drug or unstable on lithium showed intermediate levels of disruption. Treatment with lithium for 12-weeks yielded significant reductions in total and affective depression symptoms. Lithium-responders showed improvement in circadian symptoms of depression, but non-responders did not. There was no difference between lithium-responders and non-responders in affective, circadian, or total symptoms of mania.
Conclusions: Exposure to lithium is associated with reduced circadian disruption. Lithium response at 12 weeks was selectively associated with the reduction of circadian depressive symptoms. We conclude that stabilization of circadian rhythms may be an important feature of lithium's therapeutic effects. Clinical Trials Registry: NCT0127253.

Introduction:

Bipolar disorder (BD) is a devastating psychiatric disorder with an estimated prevalence of 1-2%. (1) BD has a profound negative impact on social and occupational functioning and longevity, with an estimated suicide rate of 20-30 times higher than the general population. (2) Clinically, BD is characterized by episodes of depression and mania/hypomania with disturbances in sleep, mood, energy, appetite, motivation and overall functioning. These changes in affective state, motivation and reward processing are central features of the diagnostic criteria for both depressive and manic mood episodes. (2) Disturbances in rhythmic sleep and activity cycles are manifested in both depression and mania, suggesting that circadian dysfunction is another key pathological feature of BD. Depressive episodes are typically characterized by sleep disturbances (hypersomnia, insomnia and sleep fragmentation), and decreased energy levels. Mania is defined by high energy, hyperactivity and decreased need for sleep. BD patients also show trait instability in daily activity patterns during euthymia and state instability that predicts subsequent mood symptoms (3, 4) and worsening sleep/activity disruption is often a predictor of mood relapse. (5, 6) Thus, circadian symptoms encompass the full spectrum of BD affecting depression, mania, and euthymic (maintenance) periods.

Sleep-wake cycles reflect the behavioral outputs of circadian clocks in the central nervous system. The suprachiasmatic nucleus (SCN) located in the anterior hypothalamus serves as the "master pacemaker" and synchronizes circadian rhythms throughout the body to coordinate them with external environmental cues such as light (known as "zeitgebers"), and endogenous clocks in other tissues. (7, 8) Photic input to the retina is transmitted by intrinsically photosensitive retinal ganglion cells expressing melanopsin. (9) Light signals are then relayed to the SCN and other brain clocks via direct projections from the retina. If circadian rhythms become desynchronized, this can lead to not only sleep-wake cycle disturbances, but also adverse changes in mood and related behaviors. (7-9) Accordingly, patients with BD commonly show evidence of disrupted circadian rhythms and phase delay, commonly expressed as low trait morningness and a preference for evening activity or evening chronotype. (3, 4, 10-15) Genetic studies have revealed polymorphisms in genes that encode the circadian clock and polygenic overlap between activity rhythms, chronotype and BD. (16, 17). In retrospective studies, a significant association was observed between mood relapse and circadian disruption among BD

subjects in maintenance treatment. (6, 18) These results indicate that circadian disruption may have a role as a prognostic indicator of mood stability in BD.

Lithium is hypothesized to act therapeutically by inhibiting glycogen synthase kinase 3B (GSK3B) and inositol monophosphatase (IMP) to alter the metabolism of inositol tris-phosphate (IP_3). GSK3B regulates the stability of clock proteins such as REV-ERBα, PER2, CRY2 and CLOCK (19-21) and preclinical studies indicate that lithium has direct effects on circadian rhythms. In both human and animal cell lines, lithium strengthens rhythms by increasing amplitude, and slows rhythm cycles by lengthening period. (22, 23) In a prospective study of BD patients on lithium monotherapy, baseline chronotype predicted early lithium response outcomes 12 weeks later. (24) Actigraphy studies have shown that good lithium responders show higher amplitude sleep/wake rhythms. (25) Similarly, case reports indicate correction of rhythm abnormalities in the context of successful treatment with lithium. (26) These findings indicate that circadian factors might be a key determinant of therapeutic outcomes in BD. However, it has not yet been demonstrated in a prospective study that lithium corrects rhythm disruptions including sleep and energy symptoms, and/or how lithium's effects on circadian disruption relate to the therapeutic effects of the drug and clinical response. (19, 27)

Presently, we addressed these unresolved issues in an exploratory study of a large, prospective lithium clinical trial. First, in a cross-sectional study we assessed circadian disruption in BD patients who differed in history of past lithium exposure. The aim of this analysis was to characterize morningness and circadian disturbances as they relate to past lithium exposure, and correlate these changes with mood stability. Next, we studied the relationship of circadian symptoms to lithium response by measuring changes in depression and mania in a 12-week prospective study of BD patients to determine the relationship between mood symptoms and circadian disruption over time. The overall hypothesis for both studies was that successful treatment of mood symptoms by lithium requires simultaneous resolution of circadian disruption.

Methods

Clinical Trial Study Design. PGBD was an 11-site prospective, non-randomized open trial of lithium monotherapy. The study was designed to identify genetic markers of lithium response during the maintenance phase in BD type I and details of the study have been published

previously.(28, 29) In brief, adult subjects (>18 yr. old) with BD type 1 could enter the study at any illness phase including depressed, manic, hypomanic, or mixed. To transition to lithium monotherapy, subjects either switched to lithium from another medication, or underwent dose adjustment of prior lithium treatment to optimize likelihood of response to monotherapy. Euthymic subjects already on lithium were either continued on their previous regimen or if taking another medication with lithium, were transitioned to lithium monotherapy. Euthymic subjects not on lithium were not included. Subjects on non-lithium medications had them tapered off gradually for up to 12 weeks. Exclusion criteria included medical contraindications to lithium, clinically significant thyroid and renal impairment, pregnancy, non-compliance with contraception in women of child-bearing potential, inpatient hospitalization, residential drug/alcohol treatment or inability to comply with the study protocol. Subjects were enrolled into a 12-week stabilization phase during which time, the subject met with the study physician for clinical assessment every 2 weeks, lithium was initiated, and other drugs were gradually discontinued. Clinically stabilized subjects then transitioned to maintenance treatment for a total of 2 year follow-up. For the purposes of this study, we focus on the early response to lithium. Lithium responders (Li-R) were subjects who successfully transitioned to the lithium monotherapy maintenance phase by 12 weeks. Long term (2 year) follow-up through maintenance has been reported previously and was not considered in these analyses. (29) Lithium non-responders (Li-NR) were subjects who were unable to stabilize or suffered a mood relapse prior to entering maintenance. Mood stability was defined by the absence of a mood episode relapse and a score ≤2 on the Clinician Global Inventory for Bipolar Disorder (CGI-BP). Relapse was defined as the occurrence of a depressive or manic episode using DSM-IVTR criteria, or at the discretion of the clinician using a CGI-BP score ≥4 for two consecutive weeks. Upon relapse/failure to stabilize, Li-NR subjects were excluded from the study and any subsequent analyses.

Baseline characterization of circadian phenotypes in medication groups.

All subjects were administered the full version of the Temperament Evaluation of Memphis, Pisa, Paris, and San Diego auto questionnaire. (TEMPS-A, (30)) Eleven items were selected from the TEMPS-A that ask questions related to sleep, diurnal mood variation, and energy (items 8, 21, 22, 23, 31, 32, 37, 50, 63, 101, 102). In order to estimate baseline circadian disruption,

these items were individually scored and coded as absent/present. The sum of these items endorsed by a subject was used to calculate a circadian disruption index (CDI) to estimate overall circadian disruption. CDI ranged from 0-11 with higher numbers indicating a greater degree of disruption. Subjects were also given the basic language morningness scale (BALM), a validated measure for estimating chronotype, and surrogate marker for circadian phase. (31)

Prospective changes in mood symptoms during lithium pharmacotherapy

All subjects were assessed with the QIDS-SR and CARS-M to measure symptoms of depression and mania. (32, 33) Circadian depression symptoms were defined as those directly related to sleep, energy and concentration that are known to be regulated by the circadian clock. Six items (1-4, 10 and 14) were scored 0-3 for a range of 0-18. Typically for the QIDS-SR, the items 1-4 related to sleep are scored so as to count only the most severe item. However, the items are not perfectly correlated, and may capture distinct elements of the circadian rhythm (e.g. phase and amplitude). Since we were especially interested in sleep information, we modified the QIDS-SR scoring system and counted each of these items independently for purposes of calculating depressive circadian symptoms. As a comparison, we examined QIDS-SR items 5, 11,12,13, that pertain to negative affective symptoms (feelings of sadness, poor self-appraisal, anhedonia, and suicidal thoughts). Other items focused on appetite, weight changes, feelings of restlessness and psychomotor slowing were not considered separately as they are ambiguously related to both circadian and non-circadian systems; however these items were included in the total QIDS-SR score that was calculated according to standard procedures. (33) A similar scheme was developed to assess manic symptoms. Three items from the CARS-M (items 3, 8-9) related to activity, energy and sleep were considered together as circadian manic symptoms and were scored 0-5 for a range of 0-15. For comparison, three other items related to euphoria, irritability and grandiosity (items 1-2, 7) were scored separately as positive affective symptoms, likewise scored 0-5 for a range of 0-15. Other symptoms related to thought process, speech, insight and delusions were not scored separately but were included in the total score CARS-M score that was calculated according to standard procedures. (32)

Statistical Analysis

To reduce the number of statistical comparisons in the cross-sectional study, total CDI score and BALM were analyzed as the primary outcome variables to assess circadian disruption and morningness respectively. Individual components of the CDI score were evaluated post-hoc for descriptive purposes and regarded as secondary measures. Mean group differences in the total CDI score and morningness were compared using analysis of covariance (ANCOVA) with age, sex, race as covariates to determine statistical significance (defined as $p<0.05$). A second model added two additional covariates (baseline QIDS-SR and CARS-M scores) to control for confounding of circadian function caused by mood symptoms. Afterwards, a correlation matrix was constructed to examine the relationship between individual CDI items with each other and with morningness. For these secondary, descriptive analyses, an uncorrected $p<0.05$ was used to define significantly correlated factors. A principal component analysis (PCA) was performed to examine clustering among CDI items. In the prospective study, to normalize comparison across various symptom scores and control for differences in starting symptom severity between Li-R and Li-NR, all symptom scores were transformed to z-scores based on the baseline level for each group. Changes in symptom categories (circadian, affective and total) over time were assessed separately for depression and mania using ANCOVA with age, sex, race as covariates. Group differences between Li-R and Li-NR were compared over time. Sample size decreased over time as subjects advanced to maintenance, relapsed, or were declared treatment failures. There was no effort made to impute missing results following subject drop out.

Results:

Clinical and demographic characteristics. Baseline demographics were examined separately for the larger cross-sectional study and the prospective lithium-response study. Patients in the cross-sectional study were classified into four groups: stable on lithium monotherapy (LiM), stable on lithium polytherapy with one or more other medications (LiP), unstable on lithium (ULi) and unstable on other medication (UOM). In the larger cross-sectional study, BD patients from the UOM group were on average younger and more likely to be from a non-European ethnic background compared to the other groups (Table 1). Only a fraction of the UOM subjects (88/153) went on to participate in the prospective study. There were no significant differences in demographic features between UOM subjects who did/did not participate. In the prospective

study, there were no significant differences between Li-R and Li-NR in age, sex or racial group (Table 1).

Lithium exposure in BD patients is associated with reduced circadian disruption index. Since low trait morningness has been associated with BD in previous studies, (12, 16) we looked at chronotype across groups. After adjusting for demographic factors, the LiM group had the highest morningness scores, followed by LiP and ULi respectively (Table 2). The UOM group showed significantly lower morningness scores (Figure 1A). We then analyzed CDI in the same four groups to assess disruptions in sleep, activity, and diurnal changes in affect. CDI differed significantly across the four medication groups. LiM patients had the lowest CDI (3.1 ± 0.22), whereas LiP and ULi groups had similar CDI scores of 4.7 ± 0.29 and 4.8 ± 0.31 respectively. UOM patients had the highest CDI burden of 6.15 ± 0.16, significantly higher than any of the other three groups (Figure 1A). While depressive and manic symptoms were positively associated with CDI, the group differences in CDI remained significant after additional covariates for manic and depressive symptoms were added to the model. Upon examination of the individual symptoms, the group differences were consistently and significantly higher in the UOM group and lower in the LiM group across the majority (9/11) of items (Table 2). Individual CDI items were highly inter-related (Figure 1B) and fell into one of three clusters (Figure 1C): The first includes items related to low energy (low energy, sleep >9 h, often tired), the second relate to instability in sleep/wake cycles (mood and energy shift, sleep need varies, diurnal mood changes-better in the evening, sleep not restful, early insomnia). The first two clusters were significantly negatively correlated with morningness (Figure 1B). The third cluster relates to excess energy states (rarely feeling tired, sleep <6 hr, diurnal mood changes-better in the morning) and was not correlated with morningness (Figure 1B). Altogether, these data suggest that any exposure to lithium, even in patients not fully responsive to the drug, is associated with greater morningness and a reduced burden of circadian disruption, and that mood stability is positively associated with these indicators of circadian rhythm.

Circadian and non-circadian depressive and manic symptoms in patients treated with lithium. We then examined the clinical course of 88 UOM BD subjects as they began lithium treatment and were followed prospectively over 12 weeks. Outcomes among this group were

split evenly with 44 patients successfully stabilizing (lithium responders, Li-R) and another 44 failing to stabilize or relapsing (lithium non-responders, Li-NR, Figure S1). Li-R and Li-NR were similar in baseline CDI (mean ± SEM) Li-R 5.7 ±0.3 vs Li-NR 6.04 ±0.3, trait morningness (mean BALM ± SEM): Li-R 33.0 ±1.3 vs. Li-NR 32.0 ±1.3, and serum lithium levels (mean meq/ml ± SEM): Li-R 0.61 ±0.03 vs Li-NR 0.59 ±0.03. None of these were significantly different between groups. Depressive symptoms in both Li-R and Li-NR at baseline were moderate range and not significantly different between groups (mean QIDS-SR ± SEM): 11.0 ±0.9 Li-R vs. 11.4 ±0.8 Li-NR. Manic symptoms in both groups were in the mild range and not significantly different between groups (mean CARS-M ± SEM): Li-R 8.1 ±1.0 vs Li-NR 8.5 ±0.9. After starting lithium, depression was gradually and significantly reduced in the Li-R group across all measures: total, affective and circadian symptoms, and the degree of improvement was similar for the circadian symptoms and non-circadian symptoms alike (Figure 2A). In Li-NR, total and affective depressive symptoms also significantly improved in a manner similar to the Li-R patients. However, among Li-NR, the reduction of circadian depressive symptoms by lithium was attenuated and failed to improve significantly over time (Figure 2B). In other words, the failure of circadian depressive symptoms to resolve was specifically associated with subsequent destabilization/relapse and drop out from the study. Symptoms of mania were tracked in the same way over 12 weeks of treatment with lithium (Figure 2C-D). Unlike with depressive symptoms, manic symptoms across all measures (total, affective and circadian) significantly improved in both the Li-R and Li-NR groups.

Discussion:

Circadian disruption is a hallmark of BD, with prominent roles in both the depressive (e.g. insomnia, low energy) and manic (e.g. high energy, decreased need for sleep) illness phases. In maintenance treatment of BD, circadian rhythm disorders and insomnia are commonly predictors of mood relapse. (5) While lithium is widely accepted as an effective treatment for BD and has effects on the circadian clock, it has not been clearly established that lithium is effective specifically for the treatment of circadian rhythm disruptions such as insomnia and low energy, or that restoration of rhythms is necessary for an overall favorable response to lithium treatment. The results of this exploratory study on the early stages of lithium response suggest that

compared to BD patients on other medications, any therapeutic exposure to lithium is associated with improvements in circadian rhythm disruption independently of mood symptoms, even in patients who are not fully stabilized. When studied prospectively over 12 weeks, improving circadian function is associated with overall resolution of depressive symptoms and favorable response to lithium. (34) Taken together, these findings indicate that actions of lithium on the circadian clock, especially improvements in sleep and energy may be essential for achieving initial mood stability early in the treatment of BD.

Morning chronotype is commonly associated with a variety of mental health outcomes including better response to lithium and overall well-being. (24, 35) LiM subjects stable on lithium monotherapy at the time of initial assessment had higher trait morningness and approximately 50% less circadian disruption compared to UOM subjects without previous lithium exposure. Smaller but significant differences in CDI were also seen in LiM compared to LiP and ULi patients, indicating that the lithium-responsive LiM BD group had comparatively less circadian disruption compared to lithium non-responsive or previously untreated BD patients. Patients with past exposure to lithium but with unstable mood symptoms or requiring additional medications to stabilize were characterized by less morningness and more circadian disruption compared to patients who were psychiatrically stable on lithium monotherapy. While there were significant demographic differences between groups, especially in the UOM group, differences in circadian disruption remained significant after statistical correction for these. Group differences in symptom burden of depression and mania may account for some the variance in circadian disruption, but does not full explain it. Our data therefore suggest that there are effects of lithium exposure on circadian disruption that are independent of changes in mood. However, the cross-sectional design of this part of the study could not distinguish between pharmacological effects of lithium on rhythms and individual differences in circadian rhythms that pre-date treatment.

To better characterize the pharmacological effects of lithium, we prospectively followed a cohort of BD subjects newly undergoing lithium treatment to identify changes in circadian rhythm-related mood symptoms. In this portion of the study, we demonstrated that reduction of circadian depressive symptoms was required to achieve Li-R status, defined in our study as initial resolution of mood symptoms within 12 weeks. In Li-R, resolution of affective symptoms and total depression scores closely paralleled improvements in sleep and energy. Among Li-NR,

affective symptoms and total depression scores improved significantly among subjects who remained in the study, but circadian symptoms failed to resolve, and these subjects ultimately failed treatment in subsequent study visits. Important caveats apply to the results of the Li-NR. Over the course of the trial, Li-NR subjects remained stable for varying times, but ultimately all failed to stabilize and/or relapsed. As increasing numbers of Li-NR subjects failed treatment, the size of the Li-NR group gradually diminished. Mood symptoms were not measured from subjects after leaving the study and therefore, in the Li-NR group survival bias that likely overstates the degree of overall improvement in mania and depression. Accordingly, the failure of circadian depressive symptoms to improve predicts the subsequent mood instability but not necessarily current mood instability. Taken together, these results suggest correction of circadian depressive symptoms is essential for a patient to progress early in treatment and distinguishes Li-R vs Li-NR. To the best of our knowledge, this is the first suggestion in a prospective clinical trial that the resolution of circadian disruption is essential to the therapeutic action of lithium.

There was no difference in the resolution of circadian manic symptoms in Li-R vs Li-NR, and both BD groups improved to a similar extent in each manic symptom category. Therefore, the changes in depressive circadian symptoms contribute specifically to overall lithium responsiveness. However, given that this was an outpatient study, the burden of manic symptoms among the BD subjects was low and may not have been sufficiently high to detect reductions in circadian disruption associated with severe mania. Previous work in BD patients equipped with accelerometers has demonstrated the relationships among mood, sleep and activity states, and that loss of rhythm is correlated with the severity of manic symptoms. (4, 36) Lithium is an effective treatment for acute mania, therefore there is good reason to expect in instances of severe mania, lithium may also have corrective effects on circadian disruption. Future studies of circadian rhythms and lithium in acute mania may be justified to study this question in detail.

Our work adds to a substantial body of literature revealing overlap in the therapeutic mechanisms of lithium and circadian rhythms. In a previous study of this population, chronotype predicted lithium-responsiveness: Higher morningness was associated with lower baseline depressive and manic symptoms, and fewer suicide attempts. BD patients undergoing chronotherapeutic interventions for bipolar depression (partial sleep deprivation, bright light therapy and phase advance) show a more durable recovery when the interventions are paired with lithium, implying overlapping mechanisms. (37) Genetic factors have been shown to

contribute to lithium response. (38-40) While to date only a limited set of genome-wide significant loci have been identified, aggregate polygenic risk for schizophrenia and major depression negatively influence lithium response (39, 40), and genetic risk for these disorders overlaps with genetic determinants of chronotype and circadian amplitude. (17, 35, 41) Clinically this is relevant as it suggests that residual symptoms of insomnia, energy disturbance or diurnal mood variation paired with depression may portend an unsuccessful treatment course and necessitate additional steps to stabilize BD patients on lithium." In the context of previous studies, our work supports the notion that the biological correlates of lithium response overlap meaningfully with neurobiological factors supporting circadian rhythms. Future work to target circadian disruption as an augmentation strategy for lithium and explore the mechanisms in more detail is warranted.

Our study design has some inherent limitations. Subjects were enrolled for a 2 year study, making it unethical to withhold treatment. Therefore, we did not have a control group and factors unrelated to lithium may have influenced treatment outcome. Additionally, there are some symptoms of both depression and mania that did not fit neatly into our circadian vs affective dichotomy. For instance, appetite and concentration both correlate strongly with wakefulness and therefore have circadian components, but are also strongly altered by affective state and other variables. Given this ambiguity, we decided to consider some mood symptoms only in aggregate in the total QIDS-SR/CARS-M scores, but not distinctly in the circadian vs affective scheme. Another limitation of this exploratory analyses was that the study was not optimally designed to measure circadian disruption, and we were only able to measure circadian disruption indirectly. CDI score is subject to various artifacts that limit our ability to measure the circadian contribution to symptoms with precision. Moreover, we did not re-assess CDI at the end of the prospective study and cannot determine the extent of improvement or differences in Li-R and Li-NR. Future studies making use of accelerometry and other wearable devices may be able to more precisely capture changes in circadian disruption as primary outcome measures in more precise terms of behavioral/physiological variables, and allow for more comprehensive analyses of rhythms as they relate to mood symptoms. While others have previously examined the relationship of the TEMPS-A to chronotype to reveal significant associations, (42) our use of the CDI is novel and has not yet been validated in other populations. In the cross-sectional portion, LiM patients are likely overrepresented in Li-Rs. It is therefore difficult to discern the long-term effects of lithium treatment from the inherent circadian factors that may predispose a patient to

being lithium responsive prior to treatment. The prospective portion of the study addresses this issue to some extent but the sample was relatively small and after drop-out, became even smaller, especially at later times. For this reason, our results should be viewed as preliminary.

In conclusion, stabilization of sleep and energy rhythms in BD may be an important goal of lithium pharmacotherapy, and perhaps with other mood stabilizing treatments. Among Li-R, improvement of depression-associated rhythm disruption may be critical to a good therapeutic outcome. Future studies will expand upon these findings and determine in more detail precisely how lithium acts upon neurobiological systems affecting sleep and energy to promote mood stability.

Acknowledgements

This work is dedicated to the late Dr. Hagop Akiskal, an esteemed colleague and pioneer in mood disorders research. The PGBD Trial was supported by NIMH/NIGMS (MH92758), The Western Norway Regional Health Authority and the Canadian Institutes of Health Research (#64410). Secondary analyses conducted by MJM and collaborators were supported by the Department of Veterans Affairs (BX003431). MF is supported by an R25 grant from NIMH (MH101072). The authors have no biomedical financial interests or potential conflicts of interest to declare.

References

1. Muller JK, Leweke FM. Bipolar disorder: clinical overview. Med Monatsschr Pharm. 2016;39(9):363- 9.

2. Phillips ML, Kupfer DJ. Bipolar disorder diagnosis: challenges and future directions. Lancet. 2013;381(9878):1663-71.

3. Pagani L, St Clair PA, Teshiba TM, Service SK, Fears SC, Araya C, et al. Genetic contributions to circadian activity rhythm and sleep pattern phenotypes in pedigrees segregating for severe bipolar disorder. Proc Natl Acad Sci U S A. 2016;113(6):E754-61.

4. Merikangas KR, Swendsen J, Hickie IB, Cui L, Shou H, Merikangas AK, et al. Real-time Mobile Monitoring of the Dynamic Associations Among Motor Activity, Energy, Mood, and Sleep in Adults With Bipolar Disorder. JAMA Psychiatry. 2019;76(2):190-8.

5. Harvey AG. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am J Psychiatry. 2008;165(7):820-9.

6. Takaesu Y, Inoue Y, Ono K, Murakoshi A, Futenma K, Komada Y, et al. Circadian Rhythm Sleep-Wake Disorders Predict Shorter Time to Relapse of Mood Episodes in Euthymic Patients With Bipolar Disorder: A Prospective 48-Week Study. J Clin Psychiatry. 2018;79(1).

7. Gold AK, Sylvia LG. The role of sleep in bipolar disorder. Nat Sci Sleep. 2016;8:207-14.

8. Steardo L, Jr., de Filippis R, Carbone EA, Segura-Garcia C, Verkhratsky A, De Fazio P. Sleep Disturbance in Bipolar Disorder: Neuroglia and Circadian Rhythms. Front Psychiatry. 2019;10:501.

9. LeGates TA, Fernandez DC, Hattar S. Light as a central modulator of circadian rhythms, sleep and affect. Nat Rev Neurosci. 2014;15(7):443-54.

10. Takaesu Y. Circadian rhythm in bipolar disorder: A review of the literature. Psychiatry Clin Neurosci. 2018;72(9):673-82.

11. Boudebesse C, Lajnef M, Geoffroy PA, Bellivier F, Nieto I, Gard S, et al. Chronotypes of bipolar patients in remission: validation of the French version of the circadian type inventory in the FACE-BD sample. Chronobiol Int. 2013;30(8):1042-9.

12. Ahn YM, Chang J, Joo YH, Kim SC, Lee KY, Kim YS. Chronotype distribution in bipolar I disorder and schizophrenia in a Korean sample. Bipolar Disord. 2008;10(2):271-5.

13. Baek JH, Kim JS, Kim MJ, Ryu S, Lee K, Ha K, et al. Lifetime Characteristics of Evening-Preference and Irregular Bed-Rise Time Are Associated With Lifetime Seasonal Variation of Mood and Behavior: Comparison Between Individuals With Bipolar Disorder and Healthy Controls. Behav Sleep Med. 2016;14(2):155-68.

14. Wood J, Birmaher B, Axelson D, Ehmann M, Kalas C, Monk K, et al. Replicable differences in preferred circadian phase between bipolar disorder patients and control individuals. Psychiatry Res. 2009;166(2-3):201-9.

15. Giglio LM, Magalhaes PV, Andersen ML, Walz JC, Jakobson L, Kapczinski F. Circadian preference in bipolar disorder. Sleep Breath. 2010;14(2):153-5.

16. Lewis KJS, Richards A, Karlsson R, Leonenko G, Jones SE, Jones HJ, et al. Comparison of Genetic Liability for Sleep Traits Among Individuals With Bipolar Disorder I or II and Control Participants. JAMA Psychiatry. 2020;77(3):303-10.

17. Ferguson A, Lyall LM, Ward J, Strawbridge RJ, Cullen B, Graham N, et al. Genome-Wide Association Study of Circadian Rhythmicity in 71,500 UK Biobank Participants and Polygenic Association with Mood Instability. EBioMedicine. 2018;35:279-87.

18. Takaesu Y, Inoue Y, Ono K, Murakoshi A, Futenma K, Komada Y, et al. Circadian rhythm sleep-wake disorders as predictors for bipolar disorder in patients with remitted mood disorders. J Affect Disord. 2017;220:57-61.

19. McCarthy MJ. Missing a beat: assessment of circadian rhythm abnormalities in bipolar disorder in the genomic era. Psychiatr Genet. 2019;29(2):29-36.

20. Yoshikawa T, Honma S. Lithium lengthens circadian period of cultured brain slices in area specific manner. Behav Brain Res. 2016;314:30-7.

21. Campos-de-Sousa S, Guindalini C, Tondo L, Munro J, Osborne S, Floris G, et al. Nuclear receptor rev-erb-{alpha} circadian gene variants and lithium carbonate prophylaxis in bipolar affective disorder. J Biol Rhythms. 2010;25(2):132-7.

22. Li J, Lu WQ, Beesley S, Loudon AS, Meng QJ. Lithium impacts on the amplitude and period of the molecular circadian clockwork. PLoS One. 2012;7(3):e33292.

23. McCarthy MJ, Wei H, Marnoy Z, Darvish RM, McPhie DL, Cohen BM, et al. Genetic and clinical factors predict lithium's effects on PER2 gene expression rhythms in cells from bipolar disorder patients. Transl Psychiatry. 2013;3:e318.

24. McCarthy MJ, Wei H, Nievergelt CM, Stautland A, Maihofer AX, Welsh DK, et al. Chronotype and cellular circadian rhythms predict the clinical response to lithium maintenance treatment in patients with bipolar disorder. Neuropsychopharmacology. 2019;44(3):620-8.

25. Scott J, Hennion V, Meyrel M, Bellivier F, Etain B. An ecological study of objective rest-activity markers of lithium response in bipolar-I-disorder. Psychol Med. 2020:1-9.

26. Federoff M, McCarthy MJ. Sleep and circadian rhythm disruption is corrected by lithium in a case of bipolar disorder with familial BRCA1 mutation. Bipolar Disord. 2020.

27. McCarthy MJ, Fernandes M, Kranzler HR, Covault JM, Welsh DK. Circadian clock period inversely correlates with illness severity in cells from patients with alcohol use disorders. Alcohol Clin Exp Res. 2013;37(8):1304-10.

28. Oedegaard KJ, Alda M, Anand A, Andreassen OA, Balaraman Y, Berrettini WH, et al. The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample. BMC Psychiatry. 2016;16:129.

29. Lin Y, Maihofer AX, Stapp E, Ritchey M, Alliey-Rodriguez N, Anand A, et al. Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study. Bipolar Disord. 2021.

30. Akiskal HS, Akiskal KK, Haykal RF, Manning JS, Connor PD. TEMPS-A: progress towards validation of a self-rated clinical version of the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire. J Affect Disord. 2005;85(1-2):3-16.

31. Brown FM. Psychometric equivalence of an improved Basic Language Morningness (BALM) scale using industrial population within comparisons. Ergonomics. 1993;36(1-3):191-7.

32. Altman EG, Hedeker DR, Janicak PG, Peterson JL, Davis JM. The Clinician-Administered Rating Scale for Mania (CARS-M): development, reliability, and validity. Biol Psychiatry. 1994;36(2):124-34.

33. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-83.

34. Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(Suppl 1):S31-S4.

35. Jones SE, Lane JM, Wood AR, van Hees VT, Tyrrell J, Beaumont RN, et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. Nat Commun. 2019;10(1):343.

36. Gonzalez R, Tamminga CA, Tohen M, Suppes T. The relationship between affective state and the rhythmicity of activity in bipolar disorder. J Clin Psychiatry. 2014;75(4):e317-22.

37. Wu JC, Kelsoe JR, Schachat C, Bunney BG, DeModena A, Golshan S, et al. Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biol Psychiatry. 2009;66(3):298-301.

38. International Consortium on Lithium G, Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, et al. Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study. JAMA Psychiatry. 2018;75(1):65-74.

39. Amare AT, Vaez A, Hsu YH, Direk N, Kamali Z, Howard DM, et al. Bivariate genome-wide association analyses of the broad depression phenotype combined with major depressive disorder, bipolar disorder or schizophrenia reveal eight novel genetic loci for depression. Mol Psychiatry. 2020;25(7):1420-9.

40. Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, Cearns M, et al. Association of polygenic score for major depression with response to lithium in patients with bipolar disorder. Mol Psychiatry. 2020.

41. Lyall LM, Wyse CA, Graham N, Ferguson A, Lyall DM, Cullen B, et al. Association of disrupted circadian rhythmicity with mood disorders, subjective wellbeing, and cognitive function: a cross-sectional study of 91 105 participants from the UK Biobank. Lancet Psychiatry. 2018;5(6):507-14.

42. Chrobak AA, Tereszko A, Dembinska-Krajewska D, Arciszewska A, Dopierala E, Siwek M, et al. The role of affective temperaments assessed by the Temperament Evaluation of Memphis, Pisa and San Diego-Autoquestionnaire (TEMPS-A) in the relationship between morningness-eveningness and bipolarity. J Affect Disord. 2018;232:83-8.

Cross Sectional Study				
Group	Total	Mean Age	Male Sex	European Ancestry

	N=		N= (%)	N= (%)
Unstable-Other Medication (UOM)	153	39.7*	69 (45.1)	99 (64.7)*
Unstable-Lithium (ULi)	72	40.8	27 (37.5)	63 (87.5)
Stable-Lithium Polytherapy (LiP)	66	44.1	28 (42.4)	58 (87.8)
Stable-Lithium Monotherapy (LiM)	95	45.8	46 (48.4)	84 (88.4)
Statistical Test		ANOVA $p<0.005$	Chi-Squares NS	Chi-Squares $p<0.0001$
Prospective Study				
Group	Total N=	Mean Age	Male Sex N= (%)	European Ancestry N= (%)
Li-R	44	38.6	17 (38.6)	31 (70.4)
Li-NR	44	40.1	18 (40.1)	27 (61.3)
Statistical Test		T-test NS	Chi-Squares NS	Chi-Squares NS

Table 1. Demographic features of the bipolar disorder patients initiating lithium treatment.

Circadian Trait	UOM	ULi	LiP	LiM	ANOVA
Morningness	31.2	32.9	36	38.5	***
Rarely Tired	0.43	0.43	0.5	0.52	NS
Sleep <6h	0.44	0.39	0.26	0.31	*
Diurnal Mood AM>PM	0.55	0.47	0.5	0.38	***
Low Energy	0.63	0.44	0.44	0.2	***

Sleep >9h	0.43	0.33	0.3	0.2	**
Often Tired	0.73	0.54	0.46	0.29	***
Sleep Not Restful	0.72	0.54	0.47	0.23	***
Diurnal Mood PM>AM	0.61	0.4	0.39	0.24	NS
Mood & Energy Shift	0.9	0.74	0.71	0.46	***
Early Insomnia	0.75	0.58	0.61	0.29	***

Table 2: Chronotype and circadian disruption and in lithium-treated patients with bipolar disorder. Chronotype was estimated by quantifying morningness using the Basic Language Morningness scale (BALM). BALM scores range from 13-55 with higher score indicating greater morningness. Individual components of the circadian index are reported for each BD group. CDI components were selected from items on TEMPS-A scale and scored absent (1) or present (0). Group values indicate the proportion of positive scores and group mean for each component. Key: UOM = Unstable on other medication. ULi = Unstable on Lithium, LiP = Stable on lithium polytherapy, LiM = Stable on lithium monotherapy. * indicates $p<0.05$, **$p<0.005$, ***$p<0.0001$.

Figure Captions

Figure 1. A) Lithium exposure is associated with less circadian disruption. Total circadian index score is shown for each BD patient group (group mean CDI ±SEM). After controlling for demographic variables, analysis by ANCOVA shows significant group difference ($p<0.001$). Group differences remain significant ($p<0.001$) after additional covariates for depressive and

manic symptoms are added to the model. Post-hoc test indicates significant differences between the UOM group vs. each of the three lithium-treated groups (all $p<0.05$, indicated by *). Furthermore, LiM has significantly lower CDI vs LiP and ULi (all $p<0.05$, indicated by †). B) Correlation matrix showing the relationship among chronotype and components of the circadian index. Low energy states mostly negatively correlate with morningness. High energy states mostly show no significant correlation with morningness. Key: Red = positive correlation, Blue = negative correlation. The darker the color the stronger the correlation. Cut-off for nominal statistical significance (uncorrected $p<0.05$) is indicated in the key. C) Results of clustering by first two PCA components show that CDI items cluster into three groups corresponding to low energy, unstable sleep/activity cycles and excess energy states. Data suggest CDI items are meaningfully related to chronotype and conceptually coherent.

Figure 2: Circadian symptoms of depression are selectively associated with lithium-response. Change in circadian, affective and total symptoms differ between Li-R and Li-NR cohorts over 12-week follow-up. Both A) Li-R and B) Li-NR subjects demonstrated a significant reduction in total and affective symptoms of depression. However, only Li-R patients showed improvement in circadian symptoms of depression. ANCOVA controlling for age, sex and race revealed significant differences in depressive symptoms with main effects of time ($p<0.001$) and lithium-response group ($p<0.02$). Post-hoc analyses reveal significant differences in circadian depressive symptoms between Li-R and Li-NR ($p<0.01$) and trend-level differences in the reduction of affective symptoms of depression ($p=0.058$). For manic symptoms, C) Li-R and D) Li-NR improved to a similar extent in all three symptom categories. ANCOVA revealed significant reduction in all three categories of manic symptoms over time for both Li-R and Li-NR ($p<0.001$). None of the demographic variables were significantly associated with response. Sample size by visit, Li-R: N=44/39/40/32/34/27, Li-NR: N= 44/30/27/18/15/8.



bdi_13162_f1.tiff



bdi_13162_f2.tif